港股異動 | 雲頂新耀-B跌6%續刷新低 3日連跌近30% 終止腫瘤藥物授權開發
格隆匯8月18日丨雲頂新耀-B(1952.HK)再度下跌超6%,3日連跌近30%。盤中低見12.34港元續刷歷史新低價,總市值不足40億港元。公司日前宣佈與合作方簽訂終止及過渡服務協議以退回戈沙妥珠開發權益。據此,公司將獲得4.55億美元對價。而在今年6月,戈沙妥珠正式獲批國內上市,成為雲頂新耀獲准在中國上市的首款創新藥品,公司計劃於22Q4啟動其在中國的銷售。瑞信認為,吉利德(Gilead)由雲頂新耀手上重奪Trodelvy亞洲地區的許可權,為一個令人驚訝的負面消息,該行削目標價50%至21港元,仍維持其“跑贏大市”評級。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.